Ask For a Blood test to identify AR-V7 in Circulating Tumor Cells if you are starting Xtandi or Zytiga

One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not respond to Xtandi or Zytiga and will live longer if treated with a taxane based chemotherapy (docetaxel) regimen. A study in JAMA Oncology, showed that evaluating for the presence of circulating tumor cells (CTCs) with AR-V7 could optimize treatment protocols. The study looked at 161 men with progressing metastatic castration-resistant [...]

Better Predicting Advanced Prostate Cancer Outcomes with NaF-PET/CT Scans

Imaging of prostate cancer has been improving by leaps and bounds over the last few years. Current imaging techniques are not sensitive enough to give us an accurate picture of the cancer. This means that we lose predictive abilities and don’t always have adequate information to make the best treatment decisions. It also means, in some situations, that insurance will not always cover what is clearly the best treatment because we lack evidence of the actual disease state to qualify for the FDA label of certain treatments. In a move to develop better, more accurate scanning technology, a recent study [...]

New Markers To Make Better Treatment Decisions For Prostate Cancer

Making treatment decisions once you have been diagnosed with prostate cancer is difficult. Often, it is impossible to accurately and reliably be able to predict the eventual course of the cancer. Prostate cancer, besides being one of the slower growing cancers, is also one of the deadliest. So good, informed decisions are vital. The original standby prognostic markers for prostate cancer are a man’s PSA, the stage of the cancer and their Gleason grade. Given the poor quality of these markers, in the 2000s, more sensitive markers were developed, such as PSA density, % of positive cores, % of cancer [...]

PET/CT Scans More Sensitive Than CT and Bone Scans For Detecting Metastatic Prostate Cancer

According to an article in the Journal of Nuclear Medicine, researchers compared a PET/CT scan using the radiotracer F-18 DCFBC to conventional imaging modalities — an expanded Tc-99m-methylene diphosphonate (MDP) bone scan and contrast-enhanced CT of the chest, abdomen and pelvis — to detect prostate-specific membrane antigen (PSMA), which is associated with prostate cancer metastases. In a study of 17 men the researchers found that the F-18 DCFBC PET scans were able to detect a larger number of prostate cancer lesions than the other imaging modalities. The researchers found 592 positive lesions compared to 520 identified by the other methods. [...]